BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
BLFS - BioLife Solutions, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$34.00
DETAILS
HIGH:
$34.00
LOW:
$34.00
MEDIAN:
$34.00
CONSENSUS:
$34.00
UPSIDE:
41.96%
Stock News
BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago.
BioLife Solutions Reports First Quarter 2026 Financial Results
Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
4 Medical Product Stocks to Buy From a Challenging Industry
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
BioLife Solutions (NASDAQ:BLFS) Stock Crosses Below 200 Day Moving Average – Time to Sell?
BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report) shares crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $23.73 and traded as low as $21.29. BioLife Solutions shares last traded at $21.72, with a volume of 483,605 shares. Wall Street Analyst Weigh In Several research
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2026 first quarter financial results will be released on May 7, 2026.
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced it has received the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system purpose-built for frozen biologic materials.
Wall Street Analysts Think BioLife Solutions (BLFS) Could Surge 70.78%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 70.8% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
378,550 Shares in BioLife Solutions, Inc. $BLFS Purchased by Capricorn Fund Managers Ltd
Capricorn Fund Managers Ltd purchased a new stake in shares of BioLife Solutions, Inc. (NASDAQ: BLFS) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 378,550 shares of the medical equipment provider's stock, valued at approximately $9,153,000. BioLife Solutions comprises 2.2% of Capricorn
After Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for BioLife Solutions (BLFS)
The heavy selling pressure might have exhausted for BioLife Solutions (BLFS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BioLife Looks Strong For Fiscal Year 2026
BioLife Solutions has executed a successful turnaround by refocusing on core biopreservation media and vials, divesting non-core assets. BLFS expects 17–20% revenue growth in FY26, positive GAAP net income, and mid-60s gross margins, supported by dominant CGT market share. Strategic acquisitions like PanTHERA and partnerships such as QKine are set to drive ARPU expansion and next-gen product launches by late 2026.
Wall Street Analysts Believe BioLife Solutions (BLFS) Could Rally 35%: Here's is How to Trade
The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioLife Solutions (NASDAQ:BLFS) Shares Gap Up – What’s Next?
BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report)'s stock price gapped up before the market opened on Friday. The stock had previously closed at $22.48, but opened at $23.50. BioLife Solutions shares last traded at $25.01, with a volume of 191,296 shares changing hands. More BioLife Solutions News Here are the key news stories
BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.01 per share a year ago.
BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
Fourth quarter 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-year GAAP gross margin of 63% and non-GAAP adjusted gross margin of 64% for the fourth quarter GAAP net income of $2.1 million or $0.04 per share and adjusted EBITDA of $6.9 million, or 28% of total revenue for the fourth quarter Expects 2026 revenue growth of $112.5 million to $115.0 million, up 17%-20% over 2025 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2025 fourth quarter and full year financial results will be released on February 26, 2026.
BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.
BioLife Solutions (NASDAQ:BLFS) Stock Price Crosses Below 200 Day Moving Average – Time to Sell?
BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $25.12 and traded as low as $21.96. BioLife Solutions shares last traded at $22.67, with a volume of 687,757 shares trading hands.
4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Price Targets
BioLife Solutions price target raised, named a 2026 Top Pick at Northland
$34.00
(was $25.14)
Northland Securities
H.C. Wainwright Reiterates Buy Rating on BioLife Solutions (BLFS)
$32.00
(was $26.53)
Yi Chen
·
H.C. Wainwright
BioLife Solutions price target raised to $30 from $27 at H.C. Wainwright
$30.00
(was $26.25)
H.C. Wainwright
Stephens Reiterates Overweight Rating on BioLife Solutions (BLFS)
$30.00
(was $21.57)
Jacob Johnson
·
Stephens
BioLife Solutions price target raised to $30 from $23 at Craig-Hallum
$30.00
(was $25.25)
Matt Hewitt
·
Craig-Hallum
Jefferies Starts BioLife Solutions (BLFS) at Buy, 'Getting Back to Basics, Cleaner Story Post Pending Freezer Divestiture'
$22.00
(was $17.32)
Matthew Stanton
·
Jefferies